Relypsa
develops polymeric drugs for cardiovascular, metabolic and renal diseases... Read moreRelypsa
develops polymeric drugs for cardiovascular, metabolic and renal diseases... Read more
News
Dec 12, 2018
FinanzNachrichten
Relypsa: Patrick Treanor appointed President of Relypsa and member of the Executive Committee of Vifor Pharma Group
Oct 28, 2018
BioPortfolio
Relypsa: Relypsa Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 27092018 Prices from USD $250
Oct 09, 2018
Benzinga
Relypsa: Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa® at ASN Kidney Week 2018
Sep 03, 2018
BioPortfolio
Relypsa: Relypsa Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 14062018 Prices from USD $250
Jun 05, 2018
The Business Journals
Relypsa: Seeking trifecta against kidney disease, biotech team lines up $150 million IPO
May 08, 2018
PharmiWeb
Relypsa: Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa® (patiromer) With or Without Food
Apr 16, 2018
GlobalNewswire
Press Release: Relypsa : Relypsa Funds Three Innovative Research Projects on Hyperkalemia and Associated Disorders
Apr 11, 2018
GlobeNewswire
Press Release: Relypsa : Relypsa Presents Patiromer Clinical Trial Data on Serum Potassium in Patients with Hyperkalemia at the National Kidney Foundation 2018 Spring Clinical Meetings
Mar 22, 2018
BioPortfolio
Relypsa: Relypsa Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 14032018 Prices from USD $250
Nov 16, 2017
BioPortfolio
Relypsa: Relypsa Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 26102017 Prices from USD $250
Relypsa Competitors
1
2
3
4
5
6
7
8
9